🔗 Share this article

While the US undertakes unprecedented revisions to its vaccination schedules, one figure appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on COVID-19 vaccines throughout the pandemic and has concentrated on potential fatalities after Covid immunization in her brief position at the Food and Drug Administration.

Proposed Shifts to Childhood Vaccine Program

Agency leaders planned to unveil major revisions to the pediatric immunization program in December, synchronizing the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US at odds with a large portion of the world with no evidence for public health gain. This reveal has been postponed until the new year.

Instead of Vinay Prasad, Dr. Høeg is listed to present at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to head the center this calendar year.

A Shift at the Agency

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon dismantling already-approved immunizations at the FDA.

The new acting director has often pushed for ending certain childhood immunization guidelines in the US so as to align more in line with Denmark, a nation with nationalized medicine and a population roughly the population of Wisconsin’s.

To date comments, she has persisted in emphasizing on immunizations – traditionally the purview of Dr. Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Concerns Over Expertise

Høeg has little discernible experience in pharmaceutical research, approval processes or administrative roles, which has been typical for past directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since March.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in managing a major agency. She has no expertise in pharmaceutical oversight.”

Former heads of the center would “grasp laws and regulations and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who headed the center have had.”

CDER has an immense range of responsibilities at the agency, Woodcock stated.

“Everybody just pays attention on the new drug program, but the generic drug division clears thousands of generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and all of those must be managed,” Woodcock explained. “The area you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a significant leadership aspect to the role, which supervises in excess of 5,000 employees. “It is a massive management job, if you execute it properly,” Woodcock said.

Agency Reaction and Contentious Policies

In response to inquiries about Høeg’s fitness for the role and whether this appointment signifies increased cooperation among regulatory chiefs on vaccines, a press secretary said that the “questions are based on incorrect premises”.

“Her resume is consistent with the duties of her role,” the official stated, noting the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg takes over the agency head's recently launched priority voucher program, a contentious expedited medication authorization process that reportedly troubled her former heads. “How are these medications being picked for this expedited pathway? Who takes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality going on at the FDA right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards less stringent rules of all drugs, aside from shots.”

Established Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if troubling, past, critics observe. She authored a study using unconfirmed public submissions to estimate the rate of myocarditis after Covid immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the new government included changing regulations for novel immunizations and discontinuing “non-essential” vaccines, she remarked post-election on a audio program. At the agency, Høeg has allegedly suggested barring adolescent males from getting Covid vaccines.

“She is an thorough ideologue who commences with her beliefs and reverse-engineers to fit the data in a highly misleading, untruthful manner,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined other contrarians, {like|